PNH – Medxy AI

Clonal Hematopoiesis Dynamics in Aplastic Anemia Patients Undergoing Immunosuppressive Therapy: Insights and Clinical Implications

By MedXY 09/10/2026

Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.

Clinical Updates Hematology-Oncology news

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

By MedXY 01/19/2026

This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.

Clinical Updates Internal Medicine news Pediatrics Specialties

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials

By MedXY 08/03/2025

Oral iptacopan provides sustained haemolysis control and improved haemoglobin in PNH patients over 48 weeks, with a favorable safety profile, supporting its role as a new therapeutic option.